Eyeworld CME Supplements

EW MAR 2018 - Supported by unrestricted educational grants from Shire, TearLab, and TearScience

This is a supplement to EyeWorld Magazine that doctors can take a test after reading and receive CME credits for.

Issue link: http://cmesupplements.eyeworld.org/i/944604

Contents of this Issue

Navigation

Page 1 of 7

2 Customizing modern OSD therapies to individual patient needs diagnostic skills and iden- tifying the different types of ocular surface disease out there. In the past if the pa- tient wasn't complaining of ocular surface prob- lems, these issues were often ignored to focus on Figure 1. The CEDARS Dysfunctional Tear Syndrome Algorithm is not described by severity but by what type of dry eye a patient has. Based on the different diagnoses, it will predict and define what to use to treat this type of dry eye. Source: Mark Milner, MD Updates in evidence- based dry eye and guidelines for diagnostic tools to guide therapy Francis Mah, MD There are many new updates in evidence-based dry eye care. Addition- ally, new guidelines aid in using diagnostic tools to guide therapy. The fact that dry eye is an ocular surface disease has become a hot topic in ophthalmology. In 2017, three new algo- rithms were published or are pending publication, all of which have differ- ent focuses of how they approach ocular surface disease. The three algo- rithms are the CEDARS Dysfunctional Tear Syn- drome Algorithm, TFOS DEWS II, and the ASCRS Cornea Clinical Commit- tee: Preop Cataract and Refractive Surgery Algo- rithm. So why treat dry eye disease? It is one of the most common eye dis- eases seen in practice and is usually the primary or secondary reason for seeing an eyecare profes- sional. Patients with dry eye are extremely frustrat- ed, and it is important to address dry eye and other ocular surface diseases prior to surgery to im- prove surgical outcomes and patient satisfaction with laser correction, cataract surgery, and premium IOLs. Problems like ocular surface dis- ease (OSD)—both dry eye disease (DED) and meibo- mian gland dysfunction more serious problems. Nowadays, we realize that the ocular surface can affect surgical outcomes, and many patients are not aware of their ocular surface issues, Francis Mah, MD, said. We're used to think- ing that our dry eye patient is that 70-year-old patient who comes in, but the dry eye patient population is changing, with many younger pa- tients presenting with dry eye disease. We know that this is a progressive con- dition, so it makes sense to identify these patients. At some point, not only are we going to focus on therapy, but diagnosing these patients with some of the many tests avail- able can be helpful. (MGD)—are present in the majority of cataract patients, can increase risks in surgery, and if not treated, negatively impact surgical outcomes. It's also important for physicians to review the various dry eye disease symptoms, which can in- clude discomfort, dryness, burning/stinging, foreign body sensation, gritty feeling/stickiness, blur- ry vision, fluctuation in continued from page 1

Articles in this issue

Archives of this issue

view archives of Eyeworld CME Supplements - EW MAR 2018 - Supported by unrestricted educational grants from Shire, TearLab, and TearScience